Branded Legacy, Inc. (OTC: BLEG) Announces LOI to Acquire Bio-Legacy Evaluative Group, Expanding Its Intranasal Drug Delivery Portfolio
TL;DR
Branded Legacy's acquisition of Bio-Legacy positions it to dominate the high-growth intranasal drug delivery market, offering a competitive edge in addiction treatments and vaccine accessibility.
The $1.5 million Preferred D stock transaction transfers Bio-Legacy's equity, assets, and IP to Branded Legacy, with manufacturing prototyping set for Q3 2025 and market readiness by Q1 2027.
This acquisition enhances global health by improving access to affordable naloxone devices, addressing addiction treatment challenges and contributing to a healthier tomorrow.
Discover how Branded Legacy's strategic move into intranasal drug delivery could revolutionize addiction treatments with Bio-Legacy's patented naloxone device.
Found this article helpful?
Share it with your network and spread the knowledge!
Branded Legacy, Inc. (OTC: BLEG), a diversified holdings company with a focus on health and wellness solutions, has taken a significant step towards expanding its market presence by signing a non-binding Letter of Intent (LOI) to acquire Bio-Legacy Evaluative Group. This acquisition is poised to bolster Branded Legacy's entry into the lucrative intranasal drug delivery sector, specifically targeting the addiction treatment and vaccine accessibility markets. The transaction, valued at $1.5 million in Preferred D stock, will see Branded Legacy acquiring 100% of Bio-Legacy's equity, assets, and intellectual property.
Bio-Legacy Evaluative Group is recognized for its pioneering work in advanced intranasal drug delivery technologies, including a patented naloxone device designed to address the challenges of cost and dosing in the addiction treatment market. With the market for such technologies projected to exceed $1.16 billion by 2032, this acquisition represents a strategic move for Branded Legacy to position itself at the forefront of a rapidly growing industry. Following the completion of the acquisition, Amin Janmohamed, CEO of Bio-Legacy, is set to assume the roles of CEO and Chairman of Branded Legacy, bringing his expertise and vision to the company's leadership.
The acquisition is expected to pave the way for manufacturing prototyping by the third quarter of 2025, with the naloxone device anticipated to be market-ready by the first quarter of 2027. This timeline underscores Branded Legacy's commitment to not only expanding its product portfolio but also to making a tangible impact on public health by improving access to critical treatments. The move aligns with the company's broader strategy of leveraging strategic growth, innovation, and quality to enhance lives and create sustainable value for its shareholders.
For further details on the acquisition and its implications for the intranasal drug delivery market, interested parties can view the full press release here. Additional information about Branded Legacy and its initiatives can be found on the company's website at https://BrandedLegacy.com.
Curated from InvestorBrandNetwork (IBN)
